Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
06. November 2019 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website
04. September 2019 09:00 ET
|
Denali Therapeutics Inc.
Phase 1b study of DNL151 includes Parkinson’s disease patients with and without a genetic LRRK2 mutationEither DNL151 or DNL201 anticipated to be selected for potential registrational clinical trials...
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
06. August 2019 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study
05. August 2019 09:00 ET
|
Denali Therapeutics Inc.
Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for...
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
11. Juni 2019 09:00 ET
|
Denali Therapeutics Inc.
DNL310 on track to enter Phase 1/2 clinical study in Hunter Syndrome patients in 2020DNL310 utilizes Denali’s proprietary blood-brain barrier crossing enzyme transport vehicle (“ETV”) technologyTwo...
Denali Therapeutics Reports First Quarter 2019 Financial Results
08. Mai 2019 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
12. März 2019 09:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
15. Februar 2019 09:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
08. Januar 2019 09:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
10. Dezember 2018 09:00 ET
|
Denali Therapeutics Inc.
Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...